Blau Farmacêutica Future Growth
Future criteria checks 4/6
Blau Farmacêutica is forecasted to grow earnings and revenue by 16.8% and 18.4% per annum respectively. EPS is expected to grow by 15%. Return on equity is forecast to be 20.8% in 3 years.
Earnings growth rate
EPS growth rate
|Biotechs earnings growth||19.9%|
|Revenue growth rate||18.4%|
|Future return on equity||20.8%|
|Last updated||11 May 2023|
Recent future growth updates
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their EstimatesMay 14
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen NextFeb 24
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is UnlikelyOct 14
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)Aug 17
Earnings and Revenue Growth Forecasts
|Date||Revenue||Earnings||Free Cash Flow||Cash from Op||Avg. No. Analysts|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLAU3's forecast earnings growth (16.8% per year) is above the savings rate (9.7%).
Earnings vs Market: BLAU3's earnings (16.8% per year) are forecast to grow faster than the BR market (11.6% per year).
High Growth Earnings: BLAU3's earnings are forecast to grow, but not significantly.
Revenue vs Market: BLAU3's revenue (18.4% per year) is forecast to grow faster than the BR market (6.1% per year).
High Growth Revenue: BLAU3's revenue (18.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLAU3's Return on Equity is forecast to be high in 3 years time (20.8%)